Pacific Biosciences of California Stock Price, News & Analysis (NASDAQ:PACB)

$2.48 -0.09 (-3.50 %)
(As of 02/20/2018 04:00 PM ET)
Previous Close$2.48
Today's Range$2.46 - $2.59
52-Week Range$2.21 - $5.70
Volume777,623 shs
Average Volume1.30 million shs
Market Capitalization$288.30 million
P/E Ratio-2.79
Dividend YieldN/A
Beta1.41

About Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California logoPacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
SectorHealthcare
SymbolNASDAQ:PACB
CUSIP69404D10
Phone+1-650-5218000

Debt

Debt-to-Equity Ratio0.10%
Current Ratio3.75%
Quick Ratio3.15%

Price-To-Earnings

Trailing P/E Ratio-2.78651685393258
Forward P/E Ratio-3.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$93.47 million
Price / Sales3.42
Cash FlowN/A
Price / CashN/A
Book Value$0.91 per share
Price / Book2.73

Profitability

Trailing EPS($0.89)
Net Income$-92,190,000.00
Net Margins-98.63%
Return on Equity-96.55%
Return on Assets-58.68%

Miscellaneous

Employees438
Outstanding Shares128,740,000

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) issued its earnings results on Thursday, February, 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.02. The biotechnology company had revenue of $24.94 million for the quarter, compared to analysts' expectations of $21.89 million. Pacific Biosciences of California had a negative net margin of 98.63% and a negative return on equity of 96.55%. The firm's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) earnings per share. View Pacific Biosciences of California's Earnings History.

When will Pacific Biosciences of California make its next earnings announcement?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Pacific Biosciences of California.

Where is Pacific Biosciences of California's stock going? Where will Pacific Biosciences of California's stock price be in 2018?

3 analysts have issued 1 year price objectives for Pacific Biosciences of California's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Pacific Biosciences of California's share price to reach $6.27 in the next twelve months. View Analyst Ratings for Pacific Biosciences of California.

Who are some of Pacific Biosciences of California's key competitors?

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:

  • Michael W. Hunkapiller Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 68)
  • Susan K. Barnes, Chief Financial Officer, Executive Vice President, Principal Accounting Officer (Age 63)
  • Kathy P. Ordonez, Executive Vice President and Chief Commercial Officer and Director (Age 66)
  • Kevin P. Corcoran, Senior Vice President - Market Development (Age 58)
  • James Michael Phillips, Senior Vice President - Research and Development (Age 66)
  • William W. Ericson, Lead Independent Director (Age 58)
  • David Botstein Ph.D., Independent Director (Age 72)
  • Brook H. Byers Ph.D., Independent Director (Age 71)
  • Randall S. Livingston, Independent Director (Age 63)
  • John F. Milligan Ph.D., Independent Director (Age 55)

Who owns Pacific Biosciences of California stock?

Pacific Biosciences of California's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Maverick Capital Ltd. (9.65%), BlackRock Inc. (7.01%), Consonance Capital Management LP (6.08%), ArrowMark Colorado Holdings LLC (3.35%), Raging Capital Management LLC (2.74%) and Frontier Capital Management Co. LLC (1.26%). View Institutional Ownership Trends for Pacific Biosciences of California.

Who sold Pacific Biosciences of California stock? Who is selling Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was sold by a variety of institutional investors in the last quarter, including Raging Capital Management LLC, BlackRock Inc., Millennium Management LLC, Fuller & Thaler Asset Management Inc., Bank of New York Mellon Corp and Frontier Capital Management Co. LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Who bought Pacific Biosciences of California stock? Who is buying Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Maverick Capital Ltd., Spark Investment Management LLC, ING Groep NV, Deutsche Bank AG, ARK Investment Management LLC, Consonance Capital Management LP and Two Sigma Investments LP. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy Pacific Biosciences of California stock?

Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of Pacific Biosciences of California stock can currently be purchased for approximately $2.48.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $288.30 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,190,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Pacific Biosciences of California employs 438 workers across the globe.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O'brien Drive, MENLO PARK, CA 94025, United States. The biotechnology company can be reached via phone at +1-650-5218000 or via email at [email protected]


MarketBeat Community Rating for Pacific Biosciences of California (PACB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacific Biosciences of California (NASDAQ:PACB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.332.332.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.27$6.27$6.27$10.00
Price Target Upside: 55.50% upside55.50% upside55.50% upside93.05% upside

Pacific Biosciences of California (NASDAQ:PACB) Consensus Price Target History

Price Target History for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017First AnalysisDowngradeOverweight -> Equal Weight$4.00N/AView Rating Details
9/28/2017CL KingDowngradeBuy -> Neutral$6.80HighView Rating Details
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00MediumView Rating Details
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$12.00N/AView Rating Details
4/15/2016MKM PartnersInitiated CoverageNeutral$16.50N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Pacific Biosciences of California (NASDAQ:PACB) Earnings History and Estimates Chart

Earnings by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ PACB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018($0.18)N/AView Earnings Details
2/1/2018Q4 2017($0.20)($0.18)$21.89 million$24.94 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.20)($0.19)$28.29 million$23.54 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.24)($0.26)$23.34 million$20.07 millionViewListenView Earnings Details
4/26/2017Q1 2017($0.23)($0.26)$23.80 million$24.90 millionViewN/AView Earnings Details
2/2/2017Q416($0.23)($0.21)$22.84 million$25.70 millionViewListenView Earnings Details
11/2/2016Q316($0.20)($0.19)$24.68 million$25.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.21)$20.19 million$20.70 millionViewN/AView Earnings Details
4/21/2016Q1($0.25)($0.23)$18.02 million$19.10 millionViewListenView Earnings Details
2/3/2016Q4($0.02)($0.02)$36.96 million$36.28 millionViewN/AView Earnings Details
10/22/2015Q3($0.27)$0.02$15.84 million$13.90 millionViewListenView Earnings Details
8/5/2015Q215($0.14)($0.16)$26.36 million$24.94 millionViewListenView Earnings Details
5/5/2015Q115($0.27)($0.27)$13.70 million$17.65 millionViewN/AView Earnings Details
2/3/2015Q414($0.26)($0.26)$14.90 million$16.90 millionViewListenView Earnings Details
10/23/2014Q214($0.16)($0.13)$17.20 million$20.60 millionViewListenView Earnings Details
7/24/2014Q114($0.15)($0.27)$11.39 million$11.40 millionViewN/AView Earnings Details
4/30/2014($0.28)($0.28)$10.17 million$11.64 millionViewN/AView Earnings Details
2/4/2014Q413($0.27)($0.26)$9.13 million$9.10 millionViewN/AView Earnings Details
10/22/2013Q313($0.30)($0.31)$7.08 million$7.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.35)($0.33)$6.09 million$6.04 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.37)($0.37)$4.28 million$5.60 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.37)($0.39)$4.38 million$5.90 millionViewN/AView Earnings Details
10/25/2012($0.45)($0.41)ViewN/AView Earnings Details
7/26/2012($0.46)($0.40)ViewN/AView Earnings Details
5/1/2012($0.47)($0.50)ViewN/AView Earnings Details
2/7/2012($0.50)($0.42)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.60)($0.45)ViewN/AView Earnings Details
8/4/2011($0.63)($0.42)ViewN/AView Earnings Details
4/27/2011($0.67)($0.66)ViewN/AView Earnings Details
2/15/2011($0.91)($0.97)ViewN/AView Earnings Details
11/30/2010Q3 2010($39.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pacific Biosciences of California (NASDAQ:PACB) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.19)($0.19)($0.19)
Q2 20182($0.18)($0.17)($0.18)
Q3 20182($0.17)($0.16)($0.17)
Q4 20181($0.13)($0.13)($0.13)
Q1 20191($0.14)($0.14)($0.14)
Q2 20191($0.13)($0.13)($0.13)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Pacific Biosciences of California (NASDAQ:PACB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pacific Biosciences of California (NASDAQ PACB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 70.39%
Insider Trades by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Insider Trades by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ PACB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/28/2016James Michael PhillipsSVPSell20,000$8.44$168,800.00201,449View SEC Filing  
7/29/2016James Michael PhillipsSVPSell20,000$8.45$169,000.00198,949View SEC Filing  
4/25/2016James Michael PhillipsSVPSell20,000$10.29$205,800.00201,449View SEC Filing  
3/2/2015Brian B DowVPBuy2,503$4.91$12,289.73View SEC Filing  
3/2/2015Kevin P CorcoranSVPBuy2,816$4.91$13,826.56View SEC Filing  
8/19/2014William W EricsonDirectorBuy39,299$5.14$201,996.86View SEC Filing  
8/18/2014William W EricsonDirectorBuy135,155$5.09$687,938.95View SEC Filing  
8/14/2014William W EricsonDirectorBuy77,822$5.00$389,110.00View SEC Filing  
8/13/2014William W EricsonDirectorBuy29,435$4.93$145,114.55View SEC Filing  
8/12/2014William W EricsonDirectorBuy123,423$4.89$603,538.47View SEC Filing  
12/12/2013Michael HunkapillerCEOBuy100,000$4.13$413,000.001,800,000View SEC Filing  
11/21/2013Michael HunkapillerCEOBuy200,000$3.61$722,000.001,700,000View SEC Filing  
12/3/2012Michael HunkapillerCEOBuy154,100$1.75$269,675.00View SEC Filing  
11/29/2012Michael HunkapillerCEOBuy242,200$1.68$406,896.00View SEC Filing  
11/26/2012Michael HunkapillerCEOBuy186,400$1.44$268,416.00View SEC Filing  
11/20/2012Michael HunkapillerCEOBuy155,000$1.27$196,850.00View SEC Filing  
11/16/2012Michael HunkapillerCEOBuy262,300$1.16$304,268.00View SEC Filing  
8/7/2012Michael HunkapillerCEOBuy400,000$1.75$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacific Biosciences of California (NASDAQ PACB) News Headlines

Source:
DateHeadline
Biotech Stocks Research Reports Released on OvaScience, Pacific Biosciences of California, Neuralstem, and Pieris PharmaBiotech Stocks' Research Reports Released on OvaScience, Pacific Biosciences of California, Neuralstem, and Pieris Pharma
www.bizjournals.com - February 14 at 9:18 AM
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common StockPacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 13 at 9:24 AM
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common StockPacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 12 at 4:22 PM
SMRT Sequencing of Human Genomes to be Showcased at AGBT ConferenceSMRT Sequencing of Human Genomes to be Showcased at AGBT Conference
finance.yahoo.com - February 12 at 9:12 AM
Q1 2018 EPS Estimates for Pacific Biosciences of California (PACB) Reduced by AnalystQ1 2018 EPS Estimates for Pacific Biosciences of California (PACB) Reduced by Analyst
www.americanbankingnews.com - February 9 at 8:52 AM
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up - NasdaqPacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up - Nasdaq
www.nasdaq.com - February 4 at 4:35 PM
Luminex (LMNX) & Pacific Biosciences of California (PACB) Critical SurveyLuminex (LMNX) & Pacific Biosciences of California (PACB) Critical Survey
www.americanbankingnews.com - February 3 at 1:28 PM
Whats Behind Pacific Biosciences of Californias Sinking Fourth-Quarter SalesWhat's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales
www.fool.com - February 2 at 9:19 AM
What's Behind Pacific Biosciences of California's Sinking Fourth-Quarter SalesWhat's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales
finance.yahoo.com - February 2 at 9:19 AM
Pacific Biosciences of California (PACB) Posts  Earnings Results, Beats Expectations By $0.02 EPSPacific Biosciences of California (PACB) Posts Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - February 1 at 5:06 PM
Pacific Biosciences Announces Fourth Quarter and Annual 2017 Financial ResultsPacific Biosciences Announces Fourth Quarter and Annual 2017 Financial Results
finance.yahoo.com - February 1 at 4:16 PM
Pacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by BrokeragesPacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 31 at 1:34 AM
Options Traders Expect Huge Moves in Pacific Biosciences (PACB) StockOptions Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
finance.yahoo.com - January 29 at 9:26 AM
Pacific Biosciences of California (PACB) to Post Q1 2019 Earnings of ($0.12) Per Share, William Blair ForecastsPacific Biosciences of California (PACB) to Post Q1 2019 Earnings of ($0.12) Per Share, William Blair Forecasts
www.americanbankingnews.com - January 29 at 7:30 AM
Head-To-Head Survey: ABIOMED (ABMD) & Pacific Biosciences of California (PACB)Head-To-Head Survey: ABIOMED (ABMD) & Pacific Biosciences of California (PACB)
www.americanbankingnews.com - January 26 at 7:12 PM
Today’s Research Reports on Trending Tickers: MannKind Corporation and Pacific Biosciences of CaliforniaToday’s Research Reports on Trending Tickers: MannKind Corporation and Pacific Biosciences of California
finance.yahoo.com - January 26 at 9:25 AM
BGI Increases Long-Read Sequencing Capacity with Purchase of 10 PacBio Sequel SystemsBGI Increases Long-Read Sequencing Capacity with Purchase of 10 PacBio Sequel Systems
finance.yahoo.com - January 25 at 9:18 AM
Whats in Store for Pacific Biosciences (PACB) in Q4 Earnings?What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
www.zacks.com - January 24 at 9:49 AM
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
finance.yahoo.com - January 24 at 9:49 AM
Pacific Biosciences of California (PACB) to Release Earnings on WednesdayPacific Biosciences of California (PACB) to Release Earnings on Wednesday
www.americanbankingnews.com - January 24 at 3:56 AM
Pacific Biosciences of California, Inc. Fourth Quarter and Year-End 2017 Financial Results CallPacific Biosciences of California, Inc. Fourth Quarter and Year-End 2017 Financial Results Call
finance.yahoo.com - January 22 at 5:59 PM
Pacific Biosciences of California (PACB) Expected to Post Quarterly Sales of $21.69 MillionPacific Biosciences of California (PACB) Expected to Post Quarterly Sales of $21.69 Million
www.americanbankingnews.com - January 19 at 2:26 AM
-$0.19 Earnings Per Share Expected for Pacific Biosciences of California (PACB) This Quarter-$0.19 Earnings Per Share Expected for Pacific Biosciences of California (PACB) This Quarter
www.americanbankingnews.com - January 17 at 11:10 PM
Pacific Biosciences of California (PACB) Downgraded to Strong Sell at BidaskClubPacific Biosciences of California (PACB) Downgraded to Strong Sell at BidaskClub
www.americanbankingnews.com - January 13 at 1:20 PM
PacBios Library Preparation Issues Announced At A Tough Time - Seeking AlphaPacBio's Library Preparation Issues Announced At A Tough Time - Seeking Alpha
seekingalpha.com - January 10 at 10:25 AM
Pacific Biosciences Hurt by Competition in Niche MarketsPacific Biosciences Hurt by Competition in Niche Markets
finance.yahoo.com - January 10 at 10:25 AM
Pacific Biosciences of California (PACB) and Viewray (VRAY) Financial SurveyPacific Biosciences of California (PACB) and Viewray (VRAY) Financial Survey
www.americanbankingnews.com - January 9 at 5:40 PM
Pacific Biosciences of California (PACB) Lowered to Sell at Zacks Investment ResearchPacific Biosciences of California (PACB) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 3:14 PM
Pacific Biosciences of California (PACB) Given Consensus Rating of "Hold" by AnalystsPacific Biosciences of California (PACB) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 6 at 1:26 AM
Pacific Biosciences of California (PACB) Expected to Post Earnings of -$0.20 Per SharePacific Biosciences of California (PACB) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - January 1 at 5:32 AM
ETFs with exposure to Pacific Biosciences of California, Inc. : December 27, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 12:36 PM
Pacific Biosciences of California (PACB) Raised to Sell at BidaskClubPacific Biosciences of California (PACB) Raised to Sell at BidaskClub
www.americanbankingnews.com - December 21 at 10:02 PM
Pre-Market Technical Scan on Biotech Equities -- Portola Pharmaceuticals, Sarepta Therapeutics, Pacific Biosciences of California, and bluebird bioPre-Market Technical Scan on Biotech Equities -- Portola Pharmaceuticals, Sarepta Therapeutics, Pacific Biosciences of California, and bluebird bio
www.prnewswire.com - December 19 at 7:06 AM
$21.69 Million in Sales Expected for Pacific Biosciences of California (PACB) This Quarter$21.69 Million in Sales Expected for Pacific Biosciences of California (PACB) This Quarter
www.americanbankingnews.com - December 17 at 9:08 AM
 Analysts Expect Pacific Biosciences of California (PACB) Will Post Earnings of -$0.19 Per Share Analysts Expect Pacific Biosciences of California (PACB) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - December 15 at 9:22 AM
Zacks: Analysts Expect Pacific Biosciences of California (PACB) to Announce -$0.19 EPSZacks: Analysts Expect Pacific Biosciences of California (PACB) to Announce -$0.19 EPS
www.americanbankingnews.com - December 15 at 9:22 AM
Pacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by AnalystsPacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 12 at 1:56 AM
Head to Head Comparison: Accuray (ARAY) vs. Pacific Biosciences of California (PACB)Head to Head Comparison: Accuray (ARAY) vs. Pacific Biosciences of California (PACB)
www.americanbankingnews.com - December 4 at 12:02 PM
Zacks: Brokerages Expect Pacific Biosciences of California (PACB) to Announce -$0.19 Earnings Per ShareZacks: Brokerages Expect Pacific Biosciences of California (PACB) to Announce -$0.19 Earnings Per Share
www.americanbankingnews.com - November 27 at 3:16 AM
ETFs with exposure to Pacific Biosciences of California, Inc. : November 20, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : November 20, 2017
finance.yahoo.com - November 21 at 9:08 AM
PacBio And GENEWIZ Announce Winner Of The 2017 AACR SMRT GrantPacBio And GENEWIZ Announce Winner Of The 2017 AACR SMRT Grant
finance.yahoo.com - November 18 at 10:46 AM
Pacific Biosciences of California, Inc. (PACB) Given Average Recommendation of "Hold" by BrokeragesPacific Biosciences of California, Inc. (PACB) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 17 at 1:48 AM
FY2017 Earnings Estimate for Pacific Biosciences of California, Inc. (PACB) Issued By William BlairFY2017 Earnings Estimate for Pacific Biosciences of California, Inc. (PACB) Issued By William Blair
www.americanbankingnews.com - November 10 at 1:58 PM
Zacks: Analysts Expect Pacific Biosciences of California, Inc. (PACB) Will Post Quarterly Sales of $26.67 MillionZacks: Analysts Expect Pacific Biosciences of California, Inc. (PACB) Will Post Quarterly Sales of $26.67 Million
www.americanbankingnews.com - November 10 at 4:51 AM
Pacific Biosciences of California, Inc. (PACB) Stock Rating Upgraded by Zacks Investment ResearchPacific Biosciences of California, Inc. (PACB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 9 at 1:00 PM
ETFs with exposure to Pacific Biosciences of California, Inc. : November 8, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 11:02 AM
Zacks: Analysts Anticipate Pacific Biosciences of California, Inc. (PACB) to Post -$0.19 Earnings Per ShareZacks: Analysts Anticipate Pacific Biosciences of California, Inc. (PACB) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - November 8 at 2:32 PM
Pacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Pacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 8:27 AM
First Analysis Weighs in on Pacific Biosciences of California, Inc.s Q3 2018 Earnings (PACB)First Analysis Weighs in on Pacific Biosciences of California, Inc.'s Q3 2018 Earnings (PACB)
www.americanbankingnews.com - November 6 at 12:32 PM
Pacific Biosciences of California, Inc. (PACB) Downgraded by First Analysis to Equal WeightPacific Biosciences of California, Inc. (PACB) Downgraded by First Analysis to Equal Weight
www.americanbankingnews.com - November 5 at 8:57 PM

SEC Filings

Pacific Biosciences of California (NASDAQ:PACB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacific Biosciences of California (NASDAQ:PACB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacific Biosciences of California (NASDAQ PACB) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.